🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing worldwide, with figures suggesting more than 82 million instances per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, also known as a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in concurrent days. This medication, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This milestone represents a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

According to results released by a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which uses a dual-drug approach. The research enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to make available and distribute the drug in many regions with limited resources.

Doctors on the front lines have shared positive views. Having a easy-to-administer therapy like this is described as a "game-changer" for gonorrhoea control. This is deemed essential to reduce the burden of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.